Hint mode is switched on Switch off
For swift navigation between sections

Ensysce Biosciences

PDF download

Choose all Reset all
Download Cancel
Organization name
Ensysce Biosciences Inc (formerly Leisure Acquisition Corp)
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Ensysce Biosciences is a developer of prescription drugs intended to prevent drug abuse and drug overdoses. The company's abuse and overdose resistant prodrug technologies are designed to improve the care of patients with chronic pain and offer a chemical modulation that inactivates the ingredient until it is swallowed, thereby enabling clinicians to treat patients while reducing the human and economic costs associated with prescription drug abuse.

Awards

News

22/05/2026 Ensysce Biosciences: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listing
27/03/2026 Ensysce Biosciences: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
27/02/2026 Ensysce Biosciences: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard
17/11/2025 Ensysce Biosciences: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Amendments To Articles Of Incorporations Or Bylaws; Change In Fiscal Year, Other Events, Financial Statements And Exhibits
05/06/2025 Ensysce Biosciences: Changes In Registrant’s Certifying Accountant, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001716947
  • EIN
    82-2755287
Registration is required to get access.